Voyager, AbbVie to develop anti-tau gene therapies

Gene therapy company Voyager Therapeutics Inc. (NASDAQ:VYGR) partnered with AbbVie Inc. (NYSE:ABBV) to develop gene therapies to express microtubule-associated protein tau (tau; MAPT; FTDP-17) antibodies to treat Alzheimer's disease and

Read the full 307 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE